Last updated: 2026-09-05 10:48:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Soleno Therapeutics, Inc. (SLNO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Soleno Therapeutics, Inc. (SLNO) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, SLNO traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, Soleno Therapeutics, Inc. (SLNO) moved from $52,94 to $53,01, representing a gain of 0,13% ($0,07).
The stock traded between $52,91 and $53,01 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 2,08 million shares, up versus the previous seven-day period, indicating higher trading activity.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 182 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Soleno Therapeutics, Inc. (SLNO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.